Immunotherapy / CombinationFDA-approvedSecond-line
Pembrolizumab + Axitinib
How it works
Combines pembrolizumab and axitinib to block the PD-1 protein and inhibit angiogenesis in cancer cells.
Cancer types
Melanoma— All patients
Efficacy
Studies show that around 40% of patients achieved an objective response, with a median progression-free survival of approximately 6.9 months.
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.